The first was the cobas® epidermal growth factor receptor (EGFR) mutation test from Roche Molecular Diagnostics which uses cfDNA in blood to detect the EGFR gene mutation to guide clinical decision-making in lung cancer [6]. This evidence concerns the gene EGFR and lung carcinoma.